GSK-3β Regulates the Expression of P21 to Promote the Progression of Chordoma

References

• Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69–76. doi:10.1016/S1470-2045(11)70337-022300861
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Casali PG, Lo Vullo S, et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 2010;17(1):211–219. doi:10.1245/s10434-009-0740-x
   PubMed Web of Science ®Google Scholar
• Chambers KJ, Lin DT, Meier J, Remenschneider A, Herr M, Gray ST. Incidence and survival patterns of cranial chordoma in the United States. Laryngoscope. 2014;124(5):1097–1102. doi:10.1002/lary.2442024122844
   PubMed Web of Science ®Google Scholar
• Hao S, Song H, Zhang W, et al. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro Oncol. 2018;20(6):799–809. doi:10.1093/neuonc/nox24129294092
   PubMed Web of Science ®Google Scholar
• McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12(1):1–11. doi:10.1023/A:100894730173511227920
   PubMed Web of Science ®Google Scholar
• Hu W, Yu J, Huang Y, Hu F, Zhang X, Wang Y. Lymphocyte-related inflammation and immune-based scores predict prognosis of chordoma patients after radical resection. Transl Oncol. 2018;11(2):444–449. doi:10.1016/j.tranon.2018.01.01029477108
   PubMed Web of Science ®Google Scholar
• Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9(8):2431–2438. doi:10.1002/j.1460-2075.1990.tb07419.x2164470
   PubMed Web of Science ®Google Scholar
• Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci. 2011;4:40. doi:10.3389/fnmol.2011.0004022110425
   PubMed Web of Science ®Google Scholar
• Domoto T, Pyko IV, Furuta T, et al. Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107(10):1363–1372. doi:10.1111/cas.1302827486911
   PubMed Web of Science ®Google Scholar
• Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 1996;272(5264):1023–1026. doi:10.1126/science.272.5264.10238638126
   PubMed Web of Science ®Google Scholar
• Guo L, Chen D, Yin X, Shu Q. GSK-3beta promotes cell migration and inhibits autophagy by mediating the AMPK pathway in breast cancer. Oncol Res. 2019;27(4):487–494. doi:10.3727/096504018X1532339400878430037362
   PubMed Web of Science ®Google Scholar
• Dickey A, Schleicher S, Leahy K, Hu R, Hallahan D, Thotala DK. GSK-3beta inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J Neurooncol. 2011;104(1):145–153. doi:10.1007/s11060-010-0491-321161565
   PubMed Web of Science ®Google Scholar
• Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 2006;16(7):671–677. doi:10.1038/sj.cr.731007816788573
   PubMed Web of Science ®Google Scholar
• Tang QL, Xie XB, Wang J, et al. Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012;104(10):749–763. doi:10.1093/jnci/djs21022534782
   PubMedGoogle Scholar
• Baumgart S, Chen NM, Zhang JS, et al. GSK-3beta governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression. Mol Cancer Ther. 2016;15(3):491–502. doi:10.1158/1535-7163.MCT-15-030926823495
   PubMed Web of Science ®Google Scholar
• Park GB, Chung YH, Gong JH, Jin DH, Kim D. GSK-3beta-mediated fatty acid synthesis enhances epithelial to mesenchymal transition of TLR4-activated colorectal cancer cells through regulation of TAp63. Int J Oncol. 2016;49(5):2163–2172. doi:10.3892/ijo.2016.367927599658
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Harper JW, O’Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54(5):1169–1174.8118801
   PubMed Web of Science ®Google Scholar
• Wu HL, Li SM, Hu J, et al. Demystifying the mechanistic and functional aspects of p21 gene activation with double-stranded RNAs in human cancer cells. J Exp Clin Cancer Res. 2016;35(1):145. doi:10.1186/s13046-016-0423-y27639690
   PubMed Web of Science ®Google Scholar
• Boulaire J, Fotedar A, Fotedar R. The functions of the CDK-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris). 2000;48(3):190–202.10858953
   PubMedGoogle Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–414.19440234
   PubMed Web of Science ®Google Scholar
• Kosaka M, Kang MR, Yang G, Li LC. Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells. Nucleic Acid Ther. 2012;22(5):335–343. doi:10.1089/nat.2012.035422909100
   PubMed Web of Science ®Google Scholar
• Hu Z, Long T, Ma Y, et al. Correction to: downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways. J Exp Clin Cancer Res. 2020;39(1):125. doi:10.1186/s13046-020-01635-632624003
   PubMed Web of Science ®Google Scholar
• Chen H, Garbutt CC, Spentzos D, Choy E, Hornicek FJ, Duan Z. Expression and therapeutic potential of SOX9 in chordoma. Clin Cancer Res. 2017;23(17):5176–5186. doi:10.1158/1078-0432.CCR-17-017728606919
   PubMed Web of Science ®Google Scholar
• Hai B, Pan X, Du C, et al. LncRNA XIST promotes growth of human chordoma cells by regulating miR-124-3p/iASPP pathway. Onco Targets Ther. 2020;13:4755–4765. doi:10.2147/OTT.S25219532547104
   PubMed Web of Science ®Google Scholar
• Abe K, Yamamoto N, Domoto T, et al. Glycogen synthase kinase 3beta as a potential therapeutic target in synovial sarcoma and fibrosarcoma. Cancer Sci. 2020;111(2):429–440. doi:10.1111/cas.1427131808966
   PubMed Web of Science ®Google Scholar
• Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y. The role of glycogen synthase kinase-3beta (GSK-3beta) in endometrial carcinoma: a carcinogenesis, progression, prognosis, and target therapy marker. Oncotarget. 2016;7(19):27538–27551. doi:10.18632/oncotarget.848527050373
   PubMedGoogle Scholar
• Zhang H, Hou W, Wang HL, et al. GSK-3beta-regulated N-acetyltransferase 10 is involved in colorectal cancer invasion. Clin Cancer Res. 2014;20(17):4717–4729. doi:10.1158/1078-0432.CCR-13-347724982245
   PubMed Web of Science ®Google Scholar
• Chaurasia G, Malhotra S, Russ J, et al. UniHI 4: new tools for query, analysis and visualization of the human protein-protein interactome. Nucleic Acids Res. 2009;37:D657–660. doi:10.1093/nar/gkn84118984619
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–D368. doi:10.1093/nar/gkw93727924014
   PubMed Web of Science ®Google Scholar
• Liu L, Wang T, Yang X, et al. MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated beta-catenin signaling repression. J Pineal Res. 2019;67(2):e12588. doi:10.1111/jpi.1258831140197
   PubMed Web of Science ®Google Scholar
• Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell. 2008;14(5):351–353. doi:10.1016/j.ccr.2008.10.01318977324
   PubMed Web of Science ®Google Scholar
• Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. 2014;15(5):510–515. doi:10.4161/cbt.2801524521712
   PubMed Web of Science ®Google Scholar
• Kroon J, In ‘T Veld LS, Buijs JT, Cheung H, van der Horst G, van der Pluijm G. Glycogen synthase kinase-3beta inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. Oncotarget. 2014;5(19):8986–8994. doi:10.18632/oncotarget.151025344861
   PubMedGoogle Scholar
• Zeng J, Liu D, Qiu Z, et al. GSK3beta overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One. 2014;9(3):e91231. doi:10.1371/journal.pone.009123124618715
   PubMed Web of Science ®Google Scholar
• Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005;65(6):2076–2081. doi:10.1158/0008-5472.CAN-04-364215781615
   PubMed Web of Science ®Google Scholar
• Tang Z, Yang G, Wang X, et al. AKT/GSK-3β/β-catenin signaling pathway participates in erythropoietin-promoted glioma proliferation. J Neurooncol. 2020;149(2):231–242. doi:10.1007/s11060-020-03602-932909117
   PubMed Web of Science ®Google Scholar
• Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 1995;375(6527):159–161. doi:10.1038/375159a07753174
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu X, Wang H, Liu S, Hu N, Li X. Akt regulated phosphorylation of GSK-3beta/Cyclin D1, p21 and p27 contributes to cell proliferation through cell cycle progression from G1 to S/G2M phase in low-dose arsenite exposed HaCat cells. Front Pharmacol. 2019;10:1176. doi:10.3389/fphar.2019.0117631680960
   PubMed Web of Science ®Google Scholar